List of Abilify Maintena Kit drug patents

Abilify Maintena Kit is owned by Otsuka Pharm Co Ltd.

Abilify Maintena Kit contains Aripiprazole.

Abilify Maintena Kit has a total of 14 drug patents out of which 2 drug patents have expired.

Expired drug patents of Abilify Maintena Kit are:

  • US9089567
  • US8993761

Abilify Maintena Kit was authorised for market use on 28 February, 2013.

Abilify Maintena Kit is available in for suspension, extended release;intramuscular dosage forms.

Abilify Maintena Kit can be used as treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; maintenance monotherapy treatment of bipolar i disorder; treatment of schizophrenia, treatment of schizophrenia; treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia, maintenance monotherapy treatment of bipolar i disorder; treatment of schizophrenia; treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia, treatment of schizophrenia; use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia, treatment of schizophrenia, maintenance monotherapy treatment of bipolar 1 disorder; treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; treatment of schizophrenia, use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia; treatment of schizophrenia, use of aripiprazole in extended release injectable suspension; use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia, treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; treatment of schizophrenia; maintenance monotherapy treatment of bipolar i disorder.

The generics of Abilify Maintena Kit are possible to be released after 08 March, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8993761 OTSUKA PHARM CO LTD Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(4 months ago)

US8399469 OTSUKA PHARM CO LTD Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089567 OTSUKA PHARM CO LTD Method of treating cognitive impairments and schizophrenias
Jan, 2022

(1 year, 5 days ago)

US8759351 OTSUKA PHARM CO LTD Methods for administering aripiprazole
Aug, 2023

(6 months from now)

US8338428 OTSUKA PHARM CO LTD Methods for administering aripiprazole
Aug, 2023

(6 months from now)

US8722679 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(1 year, 8 months from now)

US8030313 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(1 year, 8 months from now)

US7807680 OTSUKA PHARM CO LTD Controlled release sterile injectable aripiprazole formulation and method
Oct, 2024

(1 year, 8 months from now)

US8338427 OTSUKA PHARM CO LTD Methods for administering aripiprazole
Mar, 2025

(2 years from now)

US11400087 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(10 years from now)

US10980803 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(10 years from now)

US11154553 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(10 years from now)

US11344547 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Sep, 2033

(10 years from now)

US10525057 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Mar, 2034

(11 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: Treatment of schizophrenia; Use of aripiprazole in extended release injectable suspension; Use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia; Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; Maintenance monotherapy treatment of bipolar i disorder; Maintenance monotherapy treatment of bipolar 1 disorder

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of ABILIFY MAINTENA KIT before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic